USA flag logo/image

An Official Website of the United States Government

Antithrombotic Effects of Optimized Human Apyrase

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
70949
Program Year/Program:
2006 / SBIR
Agency Tracking Number:
HL076053
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
APT THERAPEUTICS, INC.
4041 Forest Park Avenue SAINT LOUIS, MO -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2006
Title: Antithrombotic Effects of Optimized Human Apyrase
Agency: HHS
Contract: 2R44HL076053-02
Award Amount: $790,435.00
 

Abstract:

DESCRIPTION (provided by applicant): The goal of the proposed work is to develop a novel antithrombotic drug that is safer and more effective than current therapies. Phase I funding for this project supported the successful development of a novel expression system to facilitate efficient production and purification of an optimized human apyrase as antithrombotic agent. Under Phase II support, we will extend the feasibility studies of Phase I to the development of a commercial Chinese hamster ovary cell line for high yield production. We will then utilize the recombinant protein to determine whether inhibition of platelet activation with the optimized apyrase in vivo attenuates thrombosis after arterial injury in rabbits and pigs. The ultimate goal of this research will be to develop APT102 as a frontline therapy for patients undergoing percutaneous coronary intervention as well as other patients with vascular disorders induced by excessive platelet activation.

Principal Investigator:

Ridong Chen
3146086932
RCHEN@NIDUSCENTER.COM

Business Contact:

Ridong Chen
3148128054
RCHEN@NIDUSCENTER.COM
Small Business Information at Submission:

APT THERAPEUTICS, INC.
APT THERAPEUTICS, INC. 893 NORTH WARSON ROAD SAINT LOUIS, MO 63141

EIN/Tax ID: 431947715
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No